Eli Lilly, the pharmaceutical giant with a $786 billion market capitalization, announced positive results from its Phase 3b clinical trial for Taltz and Zepbound in adults with psoriatic arthritis. The combination treatment met all primary and secondary endpoints, including a significant improvement in weight loss.
In the trial, 31.7% of patients achieved an ACR50 response plus at least 10% weight reduction, compared to just 0.8% on Taltz alone. The treatment also showed improvements in fatigue scores, physical function, and mental health-related quality of life measures.
The company’s strong financial performance continues, with revenue growth of 45% over the last twelve months and a P/E ratio of 38.5. Despite this, InvestingPro data indicates that Eli Lilly is undervalued relative to its Fair Value, placing it among companies on the Most Undervalued list.
The positive trial results come as Eli Lilly maintains strong fundamentals, with a “GREAT” financial health score and an impressive Piotroski Score of 9. The company’s prescription data for Mounjaro and Zepbound has shown stable numbers, while its Ebglyss treatment demonstrated promising long-term efficacy in a Phase 3b study for eczema.
Note: I removed the unrelated information about India’s Eris Lifesciences launching a generic version of semaglutide, as it was not relevant to Eli Lilly’s announcement.
Source: https://www.investing.com/news/company-news/lillys-taltz-plus-zepbound-shows-efficacy-in-psoriatic-arthritis-trial-93CH-4586538